Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 5/20 | 0.43 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.42 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
| ▸ | MELK | Q14680 | 1/20 | 0.38 |
| ▸ | CCR4 | P51679 | 5/20 | 0.38 |
| ▸ | ABL1 | P00519 | 3/20 | 0.38 |
| ▸ | SRC | P12931 | 3/20 | 0.38 |
| ▸ | ABL2 | P42684 | 3/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | INSR | P06213 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153335 | 1.00 | NSD2 (0.43) | NSD2EHMT2SHMT2CYP2D6CYP2C19 | |
| SCHEMBL6153415 | 0.83 | NSD2 (0.40) | NSD2ABL1SRCABL2PGR | |
| SCHEMBL6153414 | 0.83 | NSD2 (0.40) | NSD2ABL1SRCABL2PGR | |
| SCHEMBL6153630 | 0.82 | PGR (0.38) | NSD2MELKABL1SRCABL2 | |
| SCHEMBL6153624 | 0.82 | PGR (0.38) | NSD2MELKABL1SRCABL2 | |
| SCHEMBL6153762 | 0.82 | CDK7 (0.41) | MELKABL1SRCABL2PGR | |
| SCHEMBL6153758 | 0.82 | CDK7 (0.41) | MELKABL1SRCABL2PGR | |
| SCHEMBL6155712 | 0.80 | MELK (0.48) | IRAK4MELKABL1SRCABL2 | |
| SCHEMBL6155718 | 0.80 | MELK (0.48) | IRAK4MELKABL1SRCABL2 | |
| SCHEMBL6154445 | 0.78 | DRD2 (0.38) | ABL1SRCABL2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | NSD2 2185/4885EHMT2 1237/4885SHMT2 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.